Abstract: This invention provides a vascular protecting agent having salt-absorption inhibitory activity with the use of alginate oligosaccharide salt absorbed by the body via degradation to an oligosaccharide, so that a patient can easily and safely ingest such agent on a routine basis. A vascular protecting agent having salt-absorption inhibitory activity comprises, as an active ingredient, alginate oligosaccharide obtained by treating sodium alginate with a Pseudoalteromonas microorganism or a processed product thereof and/or a salt thereof.

Abstract: This invention provides a vascular protecting agent having salt-absorption inhibitory activity with the use of alginate oligosaccharide salt absorbed by the body via degradation to an oligosaccharide, so that a patient can easily and safely ingest such agent on a routine basis. A vascular protecting agent having salt-absorption inhibitory activity comprises, as an active ingredient, alginate oligosaccharide obtained by treating sodium alginate with a Pseudoalteromonas microorganism or a processed product thereof and/or a salt thereof.

Abstract: Disclosed is a composition comprising, as an active ingredient, an enzyme digest that is produced by digesting a basic fraction of an animal-derived cartilage extract with an enzyme. Also disclosed is a polypeptide composition comprising, as an active ingredient, at least one polypeptide selected from specific polypeptides including a polypeptide comprising an amino acid sequence depicted in any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

Abstract: The present invention provides an oral preventive or therapeutic agent for skin damage, containing diacylglyceryl ether as an active ingredient represented by the formula (I): wherein R1 denotes C12-24 aliphatic hydrocarbon group having a degree of unsaturation of between 0 and 2; R2 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6; and R3 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6.

Abstract: Disclosed is a composition comprising, as an active ingredient, an enzyme digest that is produced by digesting a basic fraction of an animal-derived cartilage extract with an enzyme. Also disclosed is a polypeptide composition comprising, as an active ingredient, at least one polypeptide selected from specific polypeptides including a polypeptide comprising an amino acid sequence depicted in any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

Abstract: A composition for treating or preventing hyperuricemia which contains a chondroitin sulfate protein complex as an effective ingredient. Because of having an effect of lowering serum uric acid level, this composition makes it possible to provide a novel method of the treatment, the prevention and the relief of gout.

Abstract: The present invention provides an oral preventive or therapeutic agent for skin damage, containing diacylglyceryl ether as an active ingredient represented by the formula (I): wherein R1 denotes C12-24 aliphatic hydrocarbon group having a degree of unsaturation of between 0 and 2; R2 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6; and R3 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6.

Abstract: The present invention relates to aliphatic compounds of the formula I, or stereoisomers thereof, or their pharmaceutically acceptable salts: wherein A represents an optionally substituted CH3CnH(2n-2m)— (wherein n denotes an integer of 4 to 22, and m represents an unsaturation number which is an integer of 0 to 7), l represents an integer of 0 to 10, s represents 0 or 1, provided that when s is 0, p+q=4 or 5, but when s is 1, p+q=3 or 4, and in each case, either p or q is an integer of 1 or more, R represents an alkyl group having 1 to 10 carbon atoms which may be straight-chain or branched-chain, and RA represents hydrogen or an alkyl group having 1 to 10 carbon atoms which may be straight-chain or branched-chain, and their use in suppression of platelet aggregation, in suppression of inflammation, and in prevention and treatment of circulatory diseases.

Abstract: The present invention relates to aliphatic compounds of the formula I, or stereoisomers thereof, or their pharmaceutically acceptable salts: 1